

# Overview of Biomarkers for Tobacco Exposure

Mitch Zeller, JD → formerly FDA; now American Legacy Foundation

Notes:

Identify surrogate markers of potential harm & exposure  
Biomarkers are scientific yardsticks.

Key regulatory issues:

- Comprehensive regulation (manufacture, sale, marketing/advertising)
- reduced harm products should undergo pre-market eval. of science by a federal regulatory authority
- Regulatory scrutiny of tobacco products; less scrutiny for cessation products

Top areas of research → Demonstrate reduction  
of exposure & link that to reduced harm:

1) How to measure exposure reduction?

Do they exist? What steps should

be taken to measure meaningful exposure

re

2. What studies are needed to

prove or disprove reduced exposure = red. harm?

3. re: unintended consequences: What can  
we do to minimize incentives for  
continuing to smoke?

4. Minimize incentives of non-smokers  
or further to initiate

PM3003732294

- Risk Perceptions

Need to link exposure to harm reduction

- Pre-market evaluation ~~Science~~ Claims

Report from NCI forthcoming